956951-01-2

Usage

Uses

Used in Pharmaceutical Research and Development:
2-(3-nitro-1H-pyrazol-1-yl)ethanol is utilized as an intermediate in the synthesis of pharmaceuticals, contributing to the development of new drugs and therapeutic agents.
Used in Agrochemical Research and Development:
2-(3-nitro-1H-pyrazol-1-yl)ethanol also serves as an intermediate in the synthesis of agrochemicals, playing a role in the creation of products designed to enhance crop protection and yield.
Used in Organic Synthesis:
2-(3-nitro-1H-pyrazol-1-yl)ethanol is employed as a building block in organic synthesis, where its reactivity and functional groups are leveraged to construct more complex organic molecules.
Used in Chemical Engineering:
Due to its unique molecular structure, 2-(3-nitro-1H-pyrazol-1-yl)ethanol may have applications in chemical engineering, potentially contributing to the advancement of chemical processes and materials.
It is important to handle 2-(3-nitro-1H-pyrazol-1-yl)ethanol with care, as it may present certain hazards if not used properly.

Upstream product

• 26621-44-3 3-nitro-1H-pyrazole 
• 540-51-2 2-bromoethanol 
• 107-07-3 2-chloro-ethanol 
• 1003013-08-8 1-[2-(tert-butyl-dimethyl-silanyloxy)-ethyl]-3-nitro-1H-pyrazole 

Downstream Products

• 84407-13-6 2-(3-amino-1H-pyrazol-1-yl)ethan-1-ol 
• 1421856-72-5 C₁₈H₁₇FN₆O 

Relevant academic research and scientific papers

HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS

Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

NEW 5,8-DIMETHYL-9-PHENYL-5,8-DIHYDRO-6H-PYRAZOLO[3,4-H]QUINAZOLIN-2- YL)-(1 H-PYRAZOL-3-YL)-AMINES AND DERIVATIVES AS IGF-1 R/IR INHIBITORS

The present invention encompasses compounds of formula (I) wherein the groups A, R and q are defined in claim 1, their use as inhibitors of IGF-1 R, pharmaceutical compositions which contain compounds of this kind and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.

Deacetylcolchicine deriv.

Provided are 4-modified colchicine compounds and medicines using the same. Specifically provided are colchicine derivatives represented by general formula (1), salts thereof, and solvates of the same. In general formula (1), R1 is a halogen atom, a hydroxyl group, a nitro group, an amino group, or a mono-, di- or tri-fluoromethyl group; R2, R3 and R4 are each a methoxy group or a hydroxyl group, or alternatively R2 and R3, or R3 and R4 together represent a methylenedioxy group; R5 and R6 may be the same or different and are each a hydrogen atom, a C1-6 alkyl group, an arylalkyl group, a C2-6 alkenyl group, -COR7, -COOR8, -SO2R9, -CONR10R11, or -CSNR12R13, or alternatively R5 and R6 together with the nitrogen atom to which R5 and R6 are bonded may form a three- to seven-membered cyclic amino group; R7 is a C1-6 alkyl group or the like; R8 is a C1-6 alkyl group or the like; R9 is a C1-6 alkyl group or the like; R10 and R11 may be the same or different and are each a hydrogen atom, a C1-6 alkyl group, or the like; and R12 and R13 may be the same or different and are each a hydrogen atom, an alkyl group, or the like.

PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES AS JAK INHIBITORS

The present invention relates to compounds of formula (I) wherein X1 to X5, Y, Z1 to Z4, and R have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the tre

ISOINDOLINONE DERIVATIVES

The present invention relates to compounds of the formula I, as well as pharmaceutically-acceptable salts thereof, pharmaceutical compositions containing said compounds and methods of using said compounds in the treatment or prophylaxis of diseases and disorders. The compounds and compositions disclosed herein are glucokinase activators useful for the treatment or prophylaxis of metabolic diseases and disorders, for example diabetes mellitus, including type II diabetes mellitus.

INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE

The present invention aims to provide a glucokinase activator useful as a pharmaceutical agent such as an agent for the prophylaxis or treatment of diabetes, obesity and the like. A compound represented by the formula (I): wherein R1, R2, R3, R4 are as defined herein; or a salt thereof.